Cargando…

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. METHODS: This completed open-label outpatient study was conducted at 11 sites in...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchook, Gerald, Infante, Jeffrey, Arkenau, Hendrik-Tobias, Patel, Manish R., Dean, Emma, Borazanci, Erkut, Brenner, Andrew, Cook, Natalie, Lopez, Juanita, Pant, Shubham, Frankel, Arthur, Schmid, Peter, Moore, Kathleen, McCulloch, William, Grimmer, Katharine, O'Farrell, Marie, Kemble, George, Burris, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040281/
https://www.ncbi.nlm.nih.gov/pubmed/33870151
http://dx.doi.org/10.1016/j.eclinm.2021.100797
_version_ 1783677755751137280
author Falchook, Gerald
Infante, Jeffrey
Arkenau, Hendrik-Tobias
Patel, Manish R.
Dean, Emma
Borazanci, Erkut
Brenner, Andrew
Cook, Natalie
Lopez, Juanita
Pant, Shubham
Frankel, Arthur
Schmid, Peter
Moore, Kathleen
McCulloch, William
Grimmer, Katharine
O'Farrell, Marie
Kemble, George
Burris, Howard
author_facet Falchook, Gerald
Infante, Jeffrey
Arkenau, Hendrik-Tobias
Patel, Manish R.
Dean, Emma
Borazanci, Erkut
Brenner, Andrew
Cook, Natalie
Lopez, Juanita
Pant, Shubham
Frankel, Arthur
Schmid, Peter
Moore, Kathleen
McCulloch, William
Grimmer, Katharine
O'Farrell, Marie
Kemble, George
Burris, Howard
author_sort Falchook, Gerald
collection PubMed
description BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. METHODS: This completed open-label outpatient study was conducted at 11 sites in the United States and United Kingdom. Patients with previously-treated advanced metastatic solid tumors and adequate performance status and organ function were eligible. TVB-2640 was administered orally daily until PD. Dose escalation initially followed an accelerated titration design that switched to a standard 3 + 3 design after Grade 2 toxicity occurred. Disease-specific cohorts were enrolled at the MTD. Statistical analyses were primarily descriptive. Safety analyses were performed on patients who received at least 1 dose of study drug. (Clinicaltrials.gov identifier NCT02223247) FINDINGS: The study was conducted from 21 November 2013 to 07 February 2017. Overall, 136 patients received TVB-2640, 76 as monotherapy (weight-based doses of 60 mg/m(2) to 240 mg/m(2) and flat doses of 200 and 250 mg) and 60 in combination, (weight-based doses of 60 mg/m(2) to 100 mg/m(2) and flat dose of 200 mg) (55 paclitaxel, 5 docetaxel). DLTs with TVB-2640 were reversible skin and ocular effects. The MTD/RP2D was 100 mg/m(2). The most common TEAEs (n,%) with TVB-2640 monotherapy were alopecia (46; 61%), PPE syndrome (35; 46%), fatigue (28; 37%), decreased appetite (20; 26%), and dry skin (17; 22%), and with TVB-2640+paclitaxel were fatigue (29 ; 53%), alopecia (25; 46%), PPE syndrome (25; 46%), nausea (22; 40%), and peripheral neuropathy (20; 36%). One fatal case of drug-related pneumonitis occurred with TVB-2640+paclitaxel; no other treatment-related deaths occurred. Target engagement (FASN inhibition) and inhibition of lipogenesis were demonstrated with TVB-2640. The disease control rate (DCR) with TVB-2640 monotherapy was 42%; no patient treated with monotherapy had a complete or partial response (CR or PR). In combination with paclitaxel, the PR rate was 11% and the DCR was 70%. Responses were seen across multiple tumor types, including in patients with KRAS(MUT) NSCLC, ovarian, and breast cancer. INTERPRETATION: TVB-2640 demonstrated potent FASN inhibition and a predictable and manageable safety profile, primarily characterized by non-serious, reversible adverse events affecting skin and eyes. Further investigation of TVB-2640 in patients with solid tumors, particularly in KRAS(MUT) lung, ovarian, and breast cancer, is warranted. FUNDING: This trial was funded by 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.).
format Online
Article
Text
id pubmed-8040281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80402812021-04-15 First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors Falchook, Gerald Infante, Jeffrey Arkenau, Hendrik-Tobias Patel, Manish R. Dean, Emma Borazanci, Erkut Brenner, Andrew Cook, Natalie Lopez, Juanita Pant, Shubham Frankel, Arthur Schmid, Peter Moore, Kathleen McCulloch, William Grimmer, Katharine O'Farrell, Marie Kemble, George Burris, Howard EClinicalMedicine Research Paper BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. METHODS: This completed open-label outpatient study was conducted at 11 sites in the United States and United Kingdom. Patients with previously-treated advanced metastatic solid tumors and adequate performance status and organ function were eligible. TVB-2640 was administered orally daily until PD. Dose escalation initially followed an accelerated titration design that switched to a standard 3 + 3 design after Grade 2 toxicity occurred. Disease-specific cohorts were enrolled at the MTD. Statistical analyses were primarily descriptive. Safety analyses were performed on patients who received at least 1 dose of study drug. (Clinicaltrials.gov identifier NCT02223247) FINDINGS: The study was conducted from 21 November 2013 to 07 February 2017. Overall, 136 patients received TVB-2640, 76 as monotherapy (weight-based doses of 60 mg/m(2) to 240 mg/m(2) and flat doses of 200 and 250 mg) and 60 in combination, (weight-based doses of 60 mg/m(2) to 100 mg/m(2) and flat dose of 200 mg) (55 paclitaxel, 5 docetaxel). DLTs with TVB-2640 were reversible skin and ocular effects. The MTD/RP2D was 100 mg/m(2). The most common TEAEs (n,%) with TVB-2640 monotherapy were alopecia (46; 61%), PPE syndrome (35; 46%), fatigue (28; 37%), decreased appetite (20; 26%), and dry skin (17; 22%), and with TVB-2640+paclitaxel were fatigue (29 ; 53%), alopecia (25; 46%), PPE syndrome (25; 46%), nausea (22; 40%), and peripheral neuropathy (20; 36%). One fatal case of drug-related pneumonitis occurred with TVB-2640+paclitaxel; no other treatment-related deaths occurred. Target engagement (FASN inhibition) and inhibition of lipogenesis were demonstrated with TVB-2640. The disease control rate (DCR) with TVB-2640 monotherapy was 42%; no patient treated with monotherapy had a complete or partial response (CR or PR). In combination with paclitaxel, the PR rate was 11% and the DCR was 70%. Responses were seen across multiple tumor types, including in patients with KRAS(MUT) NSCLC, ovarian, and breast cancer. INTERPRETATION: TVB-2640 demonstrated potent FASN inhibition and a predictable and manageable safety profile, primarily characterized by non-serious, reversible adverse events affecting skin and eyes. Further investigation of TVB-2640 in patients with solid tumors, particularly in KRAS(MUT) lung, ovarian, and breast cancer, is warranted. FUNDING: This trial was funded by 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.). Elsevier 2021-03-30 /pmc/articles/PMC8040281/ /pubmed/33870151 http://dx.doi.org/10.1016/j.eclinm.2021.100797 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Falchook, Gerald
Infante, Jeffrey
Arkenau, Hendrik-Tobias
Patel, Manish R.
Dean, Emma
Borazanci, Erkut
Brenner, Andrew
Cook, Natalie
Lopez, Juanita
Pant, Shubham
Frankel, Arthur
Schmid, Peter
Moore, Kathleen
McCulloch, William
Grimmer, Katharine
O'Farrell, Marie
Kemble, George
Burris, Howard
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title_full First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title_fullStr First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title_full_unstemmed First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title_short First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
title_sort first-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor tvb-2640 alone and with a taxane in advanced tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040281/
https://www.ncbi.nlm.nih.gov/pubmed/33870151
http://dx.doi.org/10.1016/j.eclinm.2021.100797
work_keys_str_mv AT falchookgerald firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT infantejeffrey firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT arkenauhendriktobias firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT patelmanishr firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT deanemma firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT borazancierkut firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT brennerandrew firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT cooknatalie firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT lopezjuanita firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT pantshubham firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT frankelarthur firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT schmidpeter firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT moorekathleen firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT mccullochwilliam firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT grimmerkatharine firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT ofarrellmarie firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT kemblegeorge firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors
AT burrishoward firstinhumanstudyofthesafetypharmacokineticsandpharmacodynamicsoffirstinclassfattyacidsynthaseinhibitortvb2640aloneandwithataxaneinadvancedtumors